9 Einträge gefunden

1. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.

   1. Schnittger, S
   2. Bacher, Ulrike
   3. Haferlach, C
   4. Alpermann, T
   5. Dicker, F
   6. Sundermann, J
   7. Kern, W

   2011 - Forschungsinformationssystem des UKE
2. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.

   1. Schnittger, S
   2. Bacher, Ulrike
   3. Kern, W
   4. Alpermann, T
   5. Haferlach, C
   6. Haferlach, T

   2011 - Forschungsinformationssystem des UKE
3. Interactive diagnostics in the indication to allogeneic SCT in AML.

   1. Bacher, Ulrike
   2. Haferlach, C
   3. Schnittger, S
   4. Kern, W
   5. Kröger, Nicolaus
   6. Zander, Axel R.
   7. Haferlach, T

   2009 - Forschungsinformationssystem des UKE
4. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.

   1. Haferlach, C
   2. Bacher, Ulrike
   3. Schnittger, S
   4. Weiss, T
   5. Kern, W
   6. Haferlach, T

   2009 - Forschungsinformationssystem des UKE
5. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity.

   1. Kern, W
   2. Haferlach, C
   3. Bacher, Ulrike
   4. Haferlach, T
   5. Schnittger, S

   2009 - Forschungsinformationssystem des UKE
6. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.

   1. Haferlach, T
   2. Kohlmann, A
   3. Klein, H-U
   4. Ruckert, C
   5. Dugas, M
   6. Williams, P M
   7. Kern, W

   2009 - Forschungsinformationssystem des UKE
7. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.

   1. Schnittger, S
   2. Bacher, Ulrike
   3. Haferlach, C
   4. Dengler, R
   5. Kröber, A
   6. Kern, W
   7. Haferlach, T

   2008 - Forschungsinformationssystem des UKE
8. A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.

   1. Schnittger, S
   2. Bacher, Ulrike
   3. Kern, W
   4. Haferlach, T
   5. Hertenstein, B
   6. Haferlach, C

   2008 - Forschungsinformationssystem des UKE
9. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.

   1. Schnittger, S
   2. Bacher, Ulrike
   3. Kern, W
   4. Haferlach, T
   5. Haferlach, C

   2007 - Forschungsinformationssystem des UKE